Ann: Change of Director's Interest Notice - PH, page-27

Correction : Imugene did not bank $1,738,657 today. Paul Hopper received the 112,171,446 consideration shares in lieu of Milestone 3 fees valued at $1,738657 (112,171,446 @ $0.0155), for meeting Phase 1 safety endpoints excluding efficacy and dose.

Imugene Limited Annual Report 30 June 2023 Financial Statements page 74
12. CONTINGENT CONSIDERATION (CONTINUED)
(b) CF33 intellectual property (continued)The key financial terms of the purchase include a cash payment of $97,588 and the issue of 127,994,355 shares in Imugene Limited, which was paid in 2021. For further details, please refer to note 5b.
There is a consideration element of three earnout components should certain milestones be achieved:

Milestone 1. Allowance of investigational new drug by the US Food and Drug Administration in relation to CF33
119,354,838 Consideration shares
Milestone 2. Dosing of first patient in a Phase 1 clinical trial for CF33
134,258,064 Consideration shares
Milestone 3. Meeting Phase 1 safety endpoints excluding efficacy and dose
149,193,548 Consideration shares

In 2022, milestones 1 and 2 were met and settled in shares.

Further notes from Imugene Limited Annual Report 30 June 2020 Financial Statements page 65
Milestone fees : $2,312,500 payable upon Meeting Phase 1 safety endpoints excluding efficacy and dose.

Total issue details today : Milestone 3 fees settled by Imugene by issuing 149,193,548 consideration shares @ $0.0155 = $2,312,500.

Regards.